Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

MGC Pharmaceuticals: Early research data shows cannabis combo could hit brain cancer

MGC Pharmaceuticals: Early research data shows cannabis combo could hit brain cancer

Proactive Research analyst Robin Davison joins Proactive's Katie to talk about MCG Pharmaceuticals' work with cannabinoids to combat brain cancer cells.

The company has reported some new data from preclinical laboratory studies done by its research collaborator, Slovenia's National Institute of Biology.

The data highlights the possible use of cannabinoids in the treatment of glioblastoma multi-formed (GBM), the aggressive, and most common, brain cancer.

Click here to read the report

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK